Chronic Hepatitis C
Conditions
Keywords
Chronic Hepatitis C, Genotype 3, High viral load
Brief summary
The rate of sustained virological response (SVR) in patients with chronic hepatitis C, genotype 3, high viral load and without rapid virological response (RNA-HCV negative at week 4) is low. Standard of care of these patients include treatment with weekly peginterferon plus 800 mg/day of ribavirin (RBV). Extended treatment to 48 weeks does not provide more clinical benefit than the standard duration. The main hypothesis is that higher dose of ribavirin may be better in terms of SVR than the standard dose.
Detailed description
Aims: 1. Efficacy 1.1) Rate of RNA-HCV negative at week 4 and 24 in each arm. 1.2) Rate of SVR in each arm. 2. Safety 2.1) Rate of adverse effects in each arm. Design: Randomized controlled trial. Patients will be randomly allocated into three arms: Arm A : Peginterferon α-2a (180 μg/week)SC. plus Ribavirin (800 mg/day) p.o. over 24 weeks. Arm B: Peginterferon α-2a (180 μg/week) plus Ribavirin (1600 mg/day) with support of Epoetin β (450 IU/kg/week) SC over 4 weeks: B1.- If RNA-HCV undetectable at week 4, standard of care will be continued (Peginterferon α-2a, 180 μg/wee plus Ribavirin (800 mg/day) over 20 additional weeks). B2.- If RNA-HCV were detectable at week 4, treatment will be continued with peginterferon α-2a (180 μg/week) plus RBV(1,600 mg/day) plus Epoetin β (450 UI/kg/week) over 20 additional weeks. Sample size: 111 patients. To increase the SVR from 50% to 75%. Beta: 0.1; alfa: 0.05; Loss: 15%. Randomization will be 1:2, 37 patients in Group A and 74 patients in group B.
Interventions
DRUGPeginterferon alfa 2 A
Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)
DRUGPeginterferon alfa 2 A, ribavirin + Epo Beta
Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb\>12g/dl over 4 or 24 weeks
DRUGribavirin
RBV 1600 mg/day 24 weeks
DRUGPeginterferon alfa 2
Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
Sponsors
Dr. Conrado Fernandez
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* HCV Genotype 3 * RNA-HCV \> \> 600.000 IU/ml. * Compromise to use contraceptive measures on treatment until 6 months after the end of treatment.
Exclusion criteria
* Pregnant or breastfeeding females. * Concurrent treatment with antineoplastic or immunomodulatory agents, including corticosteroids or radiation therapy over the last 6 months before starting the trial * Treatment with investigational drugs \< 6 weeks before starting the trial * Chronic liver disease other than hepatitis C. * Evidence of hepatocellular carcinoma. * Evidence of carcinoma hepatocellular * Decompensated liver disease * Baseline Neutrophil count \< 1500/cc; or Platelet count \< 90,000/cc * Baseline Hemoglobin \<12 g/dL in females o \<13 g/dL in males. * Increased risk of anemia(Eg, thalassemia, spherocytosis..). * Ischemic heart disease or cerebrovascular disease. * Serum creatinine \>1.5 times upper limit of normality. * History of severe psychiatric conditions (Major antidepressives or neuroleptic drugs required for major depression or psychosis), suicide attempts or psychiatric disability . * History of convulsive disorders. * Immunological conditions. * Chronic Obstructive Lung Disease with limited functionality * Severe heart disease or congestive cardiac insufficiency cardiopathy grave. * Advanced atherosclerosis * Solid organ or bone marrow transplant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of patients with RNA-HCV negative in each arm at week 24 after the end of treatment. | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Rate of patients with undetectable RNA-HCV in each arm at week 4 and 24 of treatment. Rate of adverse effects in each arm. | 1 year |
Countries
Spain
Outcome results
None listed